FTSE MIB
34.175,70 +24,29 (+0,07%) Dow Jones
39.112,49 +56,10 (+0,14%) Nasdaq
16.268,20 -34,55 (-0,21%) Nikkei 225
38.073,98 -128,39 (-0,34%) Petrolio
79,13 +0,14 (+0,18%) Bitcoin EUR
56.833,64 -869,63 (-1,51%)
MoonLake Immunotherapeutics (MLTX)
| Chiusura precedente | 42,63 |
| Aperto | 42,59 |
| Denaro | 41,84 x 200 |
| Lettera | 42,77 x 100 |
| Min-Max giorno | 42,22 - 42,79 |
| Intervallo di 52 settimane | 24,31 - 64,98 |
| Volume | |
| Media Volume | 466.857 |
| Capitalizzazione | 2,654B |
| Beta (5 anni mensile) | 1,19 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,73 |
| Prossima data utili | 12 mag 2024 - 16 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 70,93 |
GlobeNewswireMoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa (HS) Maintenance treatment with sonelokimab dosed every 4 weeks (Q4W), demonstrated that 57% of patients achieved HiSCR75 at week 24, increasing the landmark week 12 responses (primary endpoint) by over 10 ppt (percentage points)The depth of responses continued to increase fro
- GlobeNewswire
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress Peer reviewed data presented during a late-breaking session at the European Academy of Dermatology and Venereology Congress (EADV) confirms the strong profile of sonelokimab in HS announced at MLTX’s R&D Day on June 26, 2023HiSCR75 primary endpoint met with a significantly higher proportion o
- GlobeNewswire
Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress
Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress ZUG, Switzerland, October 4, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announces that 12-week Phase 2 MIRA trial data for the Nanobody® s
